Charles Santiago says Malaysians can’t afford the total remdesivir price of RM10,000 per patient.
Tag: intellectual property
Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
Today, the patent system in pharmaceuticals all too often restricts the open sharing of information, prevents further innovation by...
The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements...
Letter
Posted on
Cooperation, Not Coercion Is The Key To New Covid-19 Treatments And Cures – Philip Stevens & Mark Schultz
The existence of IP rights has enabled a rapid response by the private sector.
The Pharmaceutical Research and Manufacturers of America wants the Trump administration to reverse compulsory licensing in Malaysia and end...
Malaysia and other ASEAN countries have many strengths that can transform them into global innovation leaders.
Voluntary licences can lead to an extra 54 to 69 people annually receiving Hepatitis C treatment per 1,000 individuals...
Malaysia’s ROSE system makes it easy for women to get screened for cervical cancer. Like all digital health systems,...
A US think tank warns Malaysia about compulsory licensing of Hepatitis C medicine, sofosbuvir, becoming a trade issue.